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The efficacy and safety of methsuximide (MSM) was evaluated in children with intractable epilepsies in a prospective uncon-
trolled study.
MSM was added to the therapeutic regimen of 112 children with intractable epilepsy under inpatient conditions, all of whom
were therapeutically refractory to various first-line antiepileptic drugs (AED) or combinations of other AED. Titration of MSM
was performed following a uniform protocol.
Administration of MSM resulted in a 50% or greater reduction in seizure frequency in 40 patients after a short-term obser-
vation period (mean 9.1 weeks). After a mean of 3.7 years, the rate of seizures and side effects were re-evaluated in 39 patients
who were still receiving MSM as part of their antiepileptic regimen. Twenty two of these patients derived long-term bene-
fit from MSM. In patients with good seizure control, fasting plasma levels of N-desmethylmethsuximide, the principal active
metabolite of MSM, were 25.3–44.7 mg l−1 (mean 36.0 mg l−1). Thus effective plasma levels of N-desmethylmethsuximide
in children were found to be higher than previously described. Forty one of 112 patients (28.9%) developed side effects during
MSM treatment. No serious or irreversible side effects were seen. Our study demonstrates the value of MSM as an ‘add-on’
drug in intractable epilepsies.
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INTRODUCTION
In 1951 methsuximide (Celontinr, Petinutinr) was
found to be an antiepileptic agent when Chen1 and
Miller2, 3 tested several succinimides for their seizure
inhibiting properties. After its introduction in the
United States in 1957 it became a widely used drug,
mainly (but not only) for the control of absence
seizures4. However, its use declined after ethosux-
imide was shown to be even more effective and less
toxic in absences. Currently the use of MSM is re-
stricted to epilepsy centres, where it is used in com-
bination with other established antiepileptic drugs
(AED) for intractable epilepsies.
N-Desmethylmethsuximide is the active metabolite
of methsuximide (MSM) and is found in the serum
of patients taking MSM at levels 700 times greater
than those of the parent drug5. The mechanisms of
action of MSM are not known and are possibly mul-
tiple6. In combination therapy MSM raises the lev-
els of phenobarbital, phenytoin and primidone signif-
icantly and lowers levels of carbamazepine and val-
proic acid7, 8.
Clinical studies show efficacy of MSM against ab-
sence seizures, juvenile myoclonic epilepsy, mixed
epilepsies, Lennox–Gastaut syndrome and various
other types of epilepsy9–12 (see Table 1). There is no
prospective controlled study which shows efficacy of
MSM in defined epileptic syndromes. Side effects de-
scribed in patients under treatment with MSM are se-
dation, gastrointestinal disturbances, hiccups, ataxia,
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leukopenia and allergic rash8. Patients with MSM in-
toxication develop coma and respiratory depression13.
No fatal outcome has been published yet.
Table 1: Clinical reports on MSM.
Source, year No. of Decrease in Side-effect
patients seizure rated (%)
frequencyb (%)
Zimmerman20, 1954 90 32c 20%
Cordoba10, 1956 50 46 61%
Zimmerman21, 1956 66 38c 14%
Carter22, 1957 16 80 30%
Livingston9, 1957a 136 — 15%
Dow23, 1958 54 22c 46%
French24, 1958 106 — 38%
Scholl25, 1959 53 33 57%
Trolle26, 1959 66 71 29%
Rabe27, 1960 102 76c 15%
Dreyer19, 1969 24 43 46%
Stenzel11, 1977a 80 46 41%
Browne28, 1980 19 56c —
Wilder18, 1981 21 71c 58%
Browne8, 1983 26 31 100%
Tennison14, 1991a 25 60 36%
Hurst12, 1996 5 100 20%
a These studies focused on the use of MSM in children.
b Reported rate of patients with more than 50% (c75%) reduction
in seizure frequency.
d Reported rate of patients who developed side effects during MSM
treatment.
Of the 17 studies of MSM listed in Table 1, only
three studies focused on the use of MSM in chil-
dren9, 11, 14. Most of the studies are difficult to interpret
because of ill-defined and unspecified patient popula-
tions, seizure classifications and methods used for de-
termining therapeutic success and plasma levels of N-
desmethylmethsuximide. Stenzel et al.11 and Tennison
et al.14 reported good efficacy of MSM in epilepsies
which were refractory to modern AED treatment.
At the Pediatric Hospital of the Bethel Epilepsy
Centre, MSM is still used as a drug of further choice
in epilepsies which are not controlled by treatment
with standard AED. Since several new antiepileptic
compounds have been introduced during the last two
decades15 it seemed interesting to analyse data of
children on treatment with the ‘old’ drug MSM. We
wanted to determine if MSM should still be consid-
ered in the treatment of epilepsies.
MATERIALS AND METHODS
Data were collected prospectively from 116 consec-
utive children in whom MSM treatment was started.
Four patients were excluded from the study be-
cause neurometabolic or neurodegenerative disease
was found to be the underlying cause for the seizures.
Thus data of 112 patients were analysed.
Sixty-eight patients were male, 44 female. The mean
age at onset of MSM therapy was 8.9 years (range
15 months to 20 years). The mean duration of epilepsy
prior to consideration of MSM treatment was 6.4 years
(range 12 months to 16 years). A mean of 5.3 other
AED (SD 1.9) had been used in various combina-
tions without satisfactory result. Prior to starting the
MSM therapy, previous AED treatments and their re-
lated plasma levels had been reviewed. In cases of in-
sufficient dosage, the drugs were re-administered until
sufficient seizure control was achieved or side effects
occurred without therapeutic success before adminis-
tration of MSM was considered.
Forty of the 112 patients were classified as hav-
ing a symptomatic focal epilepsy. Thirty-eight patients
were diagnosed with Lennox–Gastaut syndrome con-
sistent with the definition of Gastaut et al. 196616.
Other diagnoses included juvenile myoclonic epilepsy
(n = 4), generalized cryptogenic (n = 4) or symp-
tomatic epilepsy (n = 4), and West syndrome (n = 3).
The period during which the AED regimen was not
altered before introduction of MSM (for a minimum
of 2 weeks; average 3.7 weeks) was considered the
baseline phase. At the beginning of the titration phase
(mean duration 5.2 weeks) MSM was started with
a single daily dose of about 5 mg kg−1. The MSM
dose was raised by increments of 3.2–5.5 mg kg−1
per week until sufficient seizure control was achieved
or side effects were observed. During titration and
treatment phases, serum concentrations of NDM and
all co-administered AED were determined weekly by
means of high performance liquid chromatography
(HPLC)17. The ratio of N-desmethylmethsuximide
serum concentrations and daily MSM doses were de-
termined in order to evaluate the individual MSM me-
tabolization rate.
For obtaining data on long-term outcome, parents,
current caregivers, pediatricians and pediatric neurol-
ogists responsible for the antiepileptic treatment were
interviewed by questionnaire and (if necessary) by
telephone.
For determining the therapeutic effect of MSM we
compared seizure frequency during the baseline phase
and during the treatment phase (short-term) or with in-
formation on seizure frequency from the questionnaire
(long-term). Accordingly, patients were classified into
the following groups:
(I) greater than 50% decrease in seizure frequency,
(II) no appreciable change (<50% decrease and
<100% increase in seizure frequency), and
(III) deterioration.
All patients with intolerable side effects were classi-
fied in group III without regard to possible reduction
of seizure frequency.
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RESULTS
A 50% or greater reduction in seizure frequency
(group I) during short-term phase (mean 9.1 weeks)
was obtained in 40 of the 112 patients (35.7%). Ten
of these patients became seizure free (8.9%). Forty-
seven patients did not show significant changes in their
seizure frequency (group II) and 25 patients became
worse (group III). Included in group III were those
patients in whom side effects prompted a discontin-
uation of MSM administration (n = 12).
Twenty-seven point 5 percent of the patients with
symptomatic focal epilepsy (n = 11) showed a 50%
or greater decrease in seizure frequency (group I—
short-term) compared to 39.5% of patients with
Lennox–Gastaut syndrome (n = 15). Ten of the
40 patients with symptomatic focal epilepsy became
worse when MSM was administered, whereas only
five of the Lennox–Gastaut patients had to be classi-
fied in group III (deterioration).
Variance analysis of reduction of seizure frequency
in relation to sex, age, epilepsy diagnosis, types of
seizures, prior drug treatment and co-medication re-
vealed no significant influence of any of these factors
on therapeutic efficacy of MSM in our patient popula-
tion.
At the time of discharge from the epilepsy Centre,
71 patients continued to take MSM as part of their
medication. Fourteen patients were lost to follow up;
thus follow up data were obtained in 57 patients.
When we re-evaluated the 57 patients after an aver-
age of 3.7 years (range 18 months to 7.1 years) we
found 39 still receiving MSM, of whom 22 (19.6%
of all 112 patients) continued to benefit from the drug
(greater than 50% decrease in seizure frequency com-
pared with baseline and absence of intolerable side ef-
fects). Six of 38 patients with Lennox–Gastaut syn-
drome and 7 of 40 patients with symptomatic fo-
cal epilepsies were classified in group I on reviewing
long-term outcome of patients on MSM.
The mean effective NDM plasma concentration of
patients in group I was 36.0 mg l−1 (SD 6.2). No
seizure inhibiting effect of MSM was documented
in children with N-desmethylmethsuximide plasma
levels below 25 mg l−1. Plasma levels of all co-
administered AED were within normal range during
treatment phase.
Side effects occurred in 41 of the 112 patients
(28.9%) while taking MSM (Table 2). In 12 of these
children MSM administration had to be discontinued
due to side effects. All side effects were completely
reversible after removal of MSM from the therapeutic
regimen or by temporary lowering of the daily dose
of MSM. There was no association of a particular side
effect with one of the co-administered AED.
Table 2: Side effects during MSM treatment.
Side effect No. of Rate (%) Mean serum
patients concentration of MSM
at occurrence of
side effect (mg l−1)
Hiccups 17 (a0) 5.2 26.5
Nausea/vomiting 16 (a3) 4.3 27.4
Drowsiness 12 (a2) 0.7 28.8
Allergic rash 6 (a3) 5.4 28.0
Aggressive behaviour 5 (a3) 4.5 32.0
Ataxia 4 (a1) 3.6 54.0
Leukopenia 2 (a0) 1.8 48.7
a The number of patients in whom this particular side effect
prompted a discontinuation of MSM treatment.
Ataxia and leukopenia were only documented with
corresponding N-desmethylmethsuximide plasma lev-
els higher than 45 mg l−1. No serious idiosyncratic,
hepatic, or renal toxicity occurred.
Metabolism of MSM appeared to be correlated with
age in a nonlinear fashion (Figure 1). Thus younger
children need higher doses of MSM compared to
older children to reach the same plasma levels of N-
desmethylmethsuximide. This effect was found to be
independent of sex, epilepsy diagnosis, therapeutic ef-
fect of MSM and of the occurrence and type of side
effects.
DISCUSSION
After several years of unsatisfactory trials to control
seizures with various combinations of different sub-
stances an additional AED is not very likely to cause
dramatic improvement in the outcome of a child with
the types of epilepsy we saw in our patient population.
Every possible effort must still be made to control or
at least to reduce the frequency of seizures in these
patients.
Compared with AED which have shown similar ef-
ficacy and safety, little has been published on MSM
and consequently little may be known about its use
especially in children. On analysing data of the ‘in-
tractable’ patients who were treated with MSM at the
Bethel Centre we found MSM not only to be effec-
tive, reducing seizure frequencies in an uncontrolled
prospective study, but also safe; no serious or irre-
versible toxicity occurred.
In contrast to reports on adult patients, in
whom plasma levels of the active metabolite N-
desmethylmethsuximide of 10–308 or 10–40 mg l−15
were reported to be effective, we found in children the
therapeutic range of the metabolite to be as high as 25–
45 mg l−1. No therapeutic effect of MSM was seen in
children with N-desmethylmethsuximide serum con-
centrations below 25 mg l−1 whereas no signs of toxi-
city occurred with corresponding plasma levels of less
than 45 mg l−1.
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Fig. 1: Metabolization of MSM in relation to age.
The median side effect rate of 16 of the 17 previ-
ous studies on MSM listed in Table 2 was 36% (mean
39.2%). With a rate of 28.9% relatively few of our
patients developed side effects. This could be due to
the fact that only three of the 17 studies8, 14, 18 con-
sidered serum concentrations and interactions of N-
desmethylmethsuximide and other AED. Thus a good
part of the side effects seen in other studies were possi-
bly caused by high or toxic plasma levels of antiepilep-
tic substances.
Leukopenia (n = 2) and ataxia (n = 4) occurred
only when N-desmethylmethsuximide plasma levels
exceeded 45 mg l−1, suggesting that these findings in
patients on MSM may be signs of toxic plasma levels
of the metabolite rather than side effects.
When using MSM, it is important to consider its
interaction with other AED such as phenytoin, prim-
idone and phenobarbital (rise in plasma levels) or
carbamazepine and valproic acid (decrease in plasma
level). Furthermore, MSM dosages should be in-
creased slowly to prevent the occurrence of gastroin-
testinal disturbances19. Plasma levels of MSM and co-
administered antiepileptic compounds should be mon-
itored at least weekly during titration and for the first
2 weeks of the treatment phase.
While newer anticonvulsant compounds are being
investigated for their efficacy and toxicity we inves-
tigated one of the old and almost forgotten AED. We
come to the conclusion that MSM is a drug with long
record and low toxicity that is potentially useful as an
‘add-on’ drug in intractable epilepsies—especially in
Lennox–Gastaut syndrome and in symptomatic focal
epilepsies before considering surgery.
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